摘要
目的研究在急性心力衰竭患者中采取冻干重组人脑利钠肽联合左西孟旦治疗的临床效果。方法选取2017年4月～2018年4月河池市第一人民医院收治的92例急性心力衰竭患者作为本次数据统计对象,按照随机数字表法将其分为研究组(n=46)和对照组(n=46)。对照组患者实行左西孟旦单独治疗,研究组患者实行冻干重组人脑利钠肽联合左西孟旦治疗。比较两组患者的临床治疗有效率;比较两组患者治疗前后的B型利钠肽水平、血清尿酸水平以及心功能指标[左心室射血分数(LVEF)和左室舒张末期内径(LVEDD)]变化情况。结果研究组患者的临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的B型利钠肽水平、血清尿酸水平以及LVEF、LVEDD比较,差异无统计学意义(P>0.05)。治疗后,研究组患者的B型利钠肽水平、血清尿酸水平明显低于对照组,LVEF、LVEDD明显高于对照组,差异有统计学意义(P<0.05)。两组患者治疗后的B型利钠肽水平、血清尿酸水平明显低于治疗前,LVEF、LVEDD明显高于治疗前,差异有统计学意义(P<0.05)。结论将冻干重组人脑利钠肽联合左西孟旦治疗应用在急性心力衰竭患者中有利于临床治疗效果的改善。
Objective To study the clinical effect of Lyophilized Recombinant Human Brain Natriuretic Peptide combined with Levosimendan in patients with acute heart failure.Methods Ninety-two patients with acute heart failure admitted to the First People's Hospital of Hechi City from April 2017 to April 2018 were selected as the data subjects.According to the random number table method,they were divided into study group(n=46)and control group(n=46).Patients in the control group were treated with Levosimendan alone,while those in the study group were treated with Lyophilized Recombinant Human Brain Natriuretic Peptide combined with Levosimendan.The clinical treatment efficiency of the two groups was compared.The changes of B-type natriuretic peptide level,serum uric acid level and cardiac function indexes(left ventricular ejection fraction[LVEF]and left ventricular end-diastolic diameter[LVEDD])before and after treatment in the two groups were compared.Results The total effective rate in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences in B-type natriuretic peptide level,serum uric acid level,LVEF and LVEDD between the two groups(P >0.05).After treatment,the level of B-type natriuretic peptide and serum uric acid in the study group were significantly lower than those in the control group,and LVEF and LVEDD were significantly higher than those in the control group,with statistically significant differences(P<0.05).After treatment,the level of B-type natriuretic peptide and serum uric acid in the two groups were significantly lower than those before treatment,and LVEF and LVEDD were significantly higher than those before treatment,with statistically significant differences(P<0.05).Conclusion The application of Lyophilized Recombinant Human Brain Natriuretic Peptide combined with Levosimendan in the treatment of acute heart failure is beneficial to the improvement of clinical treatment.
作者
杨理会
YANG Li-hui(Department of Pharmacy,the First People′s Hospital of Hechi City,Guangxi Zhuang Autonomous Region,Hechi 546300,China)
出处
《中国当代医药》
2019年第3期120-122,共3页
China Modern Medicine
关键词
急性心力衰竭
左西孟旦
冻干重组人脑利钠肽
联合治疗效果
Acute heart failure
Levosimendan
Lyophilized Recombinant Human Brain Natriuretic Peptide
Effect of combination therapy
